+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Immunohistochemical expression of nm23 in primary invasive malignant melanoma is predictive of survival outcome



Immunohistochemical expression of nm23 in primary invasive malignant melanoma is predictive of survival outcome



Journal of Pathology 190(2): 157-162



The objective of this study was to determine the utility of nm23 as an immunohistochemical indicator of prognosis in a large series (157 cases) of malignant melanoma and also in two subsets within this group: stage 1 tumours, whether in radial or vertical growth phase (140 cases); and stage 1 tumours in which a vertical growth phase component was positively identified (123 cases). A secondary objective was to explore the relationship between the immunohistochemical expression of nm23 and established clinical and histological indicators of prognosis in each of these three groups. In all groups it was found that strong immunoreactivity correlated positively with survival and inversely with indicators of poor prognosis, in keeping with transfection and mRNA studies and also with many immunohistochemical studies of other tumour types. That these findings are at variance with earlier reported immunohistochemical studies of melanoma highlights the importance of large case numbers of primary invasive tumours in studies which set out to explore the relationship between immunoreactivity and survival.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 010797213

Download citation: RISBibTeXText

PMID: 10657013

DOI: 10.1002/(sici)1096-9896(200002)190:2<157::aid-path512>3.0.co;2-j


Related references

NM23 expression in metastasis of malignant melanoma is a predictive prognostic parameter correlated with survival. British Journal of Cancer 70(6): 1224-1228, 1994

Prognostic significance of nm23-protein expression in malignant melanoma An immunohistochemical study. Pigment Cell Research 0(SUPPL 5): 47, 1996

Nm23 Gene expression correlates with length of survival in patients with thick cutaneous malignant melanoma. Journal of Pathology 175(SUPPL ): 148A, 1995

Expression of NM23 protein in acquired melanocytic nevi, malignant melanoma and metastases of malignant melanoma: an immunohistological assessment in human skin. Dermatology 194(2): 136-139, 1997

MIB-1 positivity is predictive of survival in 1 primary level IV malignant melanoma. Modern Pathology 8(1): 48A, 1995

p53 expression in cutaneous malignant melanoma: an immunohistochemical study of 87 cases of primary, recurrent, and metastatic melanoma. Modern Pathology 7(5): 533-535, 1994

Immunohistochemical demonstration of the nm23-H1 gene product in human malignant melanoma and Spitz nevi. Pathology 28(3): 220-224, 1996

Expression of Fas ligand (CD95L) in primary malignant melanoma and melanoma metastases is associated with overall survival. Onkologie 29(8-9): 361-365, 2006

An immunohistochemical analysis of nm23 gene product expression in uveal melanoma. Melanoma Research 7(3): 231-236, 1997

The loss of NM23 protein in malignant melanoma predicts lymphatic spread without affecting survival. Anticancer Research 20(5c): 3971-3974, 2001

Dermatopathological indicators of poor melanoma prognosis are significantly inversely correlated with the expression of NM23 protein in primary cutaneous melanoma. Journal of Cutaneous Pathology 34(9): 705-712, 2007

Immunohistochemical expression of p53 protein, mitotic index and nuclear morphometry in primary malignant melanoma of the skin. Pathology, Research and Practice 192(8): 825-833, 1996

Immunohistochemical analysis of nm23 protein expression in malignant bone tumors. Journal Of Cancer Research & Clinical Oncology. 121(11): 667-673, 1995

Gene expression profiling of paraffin-embedded primary melanoma using the DASL assay identifies increased osteopontin expression as predictive of reduced relapse-free survival. Clinical Cancer Research 15(22): 6939-6946, 2010

Nm23 gene product expression in invasive breast cancer--immunohistochemical analysis and clinicopathological correlation. Acta Oncologica 41(4): 355-361, 2002